Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.
Saved in:
| Title: | Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study. |
|---|---|
| Authors: | Douma, Li-Anne H1 (AUTHOR), Lalezari, Ferry2 (AUTHOR), van der Noort, Vincent3 (AUTHOR), de Vries, Jeltje F3 (AUTHOR), Monkhorst, Kim4 (AUTHOR), Smesseim, Illaa1 (AUTHOR), Baas, Paul1 (AUTHOR), Schilder, Bodien1 (AUTHOR), Vermeulen, Marrit3 (AUTHOR), Burgers, Jacobus A1 (AUTHOR) s.burgers@nki.nl, de Gooijer, Cornedine J1 (AUTHOR) |
| Source: | Lancet Oncology. Nov2023, Vol. 24 Issue 11, p1219-1228. 10p. |
| Database: | Academic Search Ultimate |
| ISSN: | 14702045 |
|---|---|
| DOI: | 10.1016/S1470-2045(23)00446-1 |
